{"filing":{"accession_number":"0001104659-26-105968","cik":"0001372299","ticker":"OCGN","company_name":"Ocugen, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-01","primary_document":"tm2624985d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926105968/tm2624985d1_8k.htm"},"events":[{"id":32094,"run_id":29483,"accession_number":"0001104659-26-105968","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Ocugen disclosed material clinical and regulatory progress for its gene therapy pipeline, including initiation of Phase 3 dosing for OCU410 in geographic atrophy following FDA alignment and RMAT designation, and a Data Monitoring Committee recommendation to continue the OCU410ST Phase 2/3 trial for Stargardt disease. The company also posted a corporate presentation detailing clinical trial data, regulatory milestones, and market potential for three programs (OCU400, OCU410ST, and OCU410).","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35178,"accession_number":"0001104659-26-105968","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ocugen disclosed a corporate presentation under Item 7.01 (Regulation FD Disclosure) that will be posted on its website and used in investor discussions. The presentation details the company's gene therapy pipeline, including clinical trial data, regulatory milestones, and market potential for three programs (OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy). While this is an operational/strategic disclosure of clinical progress and pipeline advancement rather than a discrete event like M\u0026A, litigation, or financial reporting, the detailed clinical data and regulatory pathway updates would be material to investors assessing the company's development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:28:51.113914+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35179,"accession_number":"0001104659-26-105968","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on two operational milestones for Ocugen's gene therapy pipeline: (1) initiation of Phase 3 dosing for OCU410 in geographic atrophy following FDA alignment on trial design and RMAT designation, and (2) a Data Monitoring Committee recommendation to continue the OCU410ST Phase 2/3 trial for Stargardt disease. These are material clinical development and regulatory progress events that would affect investor assessment of the company's pipeline advancement, but they do not fit neatly into predefined categories like earnings, M\u0026A, impairment, or litigation. The events are clearly operational/strategic in nature and material to the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:28:51.113914+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35178,"accession_number":"0001104659-26-105968","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ocugen disclosed a corporate presentation under Item 7.01 (Regulation FD Disclosure) that will be posted on its website and used in investor discussions. The presentation details the company's gene therapy pipeline, including clinical trial data, regulatory milestones, and market potential for three programs (OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy). While this is an operational/strategic disclosure of clinical progress and pipeline advancement rather than a discrete event like M\u0026A, litigation, or financial reporting, the detailed clinical data and regulatory pathway updates would be material to investors assessing the company's development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:28:51.113914+00:00","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-09-08"},{"id":35179,"accession_number":"0001104659-26-105968","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on two operational milestones for Ocugen's gene therapy pipeline: (1) initiation of Phase 3 dosing for OCU410 in geographic atrophy following FDA alignment on trial design and RMAT designation, and (2) a Data Monitoring Committee recommendation to continue the OCU410ST Phase 2/3 trial for Stargardt disease. These are material clinical development and regulatory progress events that would affect investor assessment of the company's pipeline advancement, but they do not fit neatly into predefined categories like earnings, M\u0026A, impairment, or litigation. The events are clearly operational/strategic in nature and material to the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:28:51.113914+00:00","company_name":"Ocugen, Inc.","ticker":"OCGN","filing_date":"2026-09-08"}]}